FYARRO® (Sirolimus protein-bound particles for injectable suspension-albumin-bound)

The FDA on November 22, 2021, approved FYARRO® for adult patients with locally advanced unresectable or metastatic malignant Perivascular Epithelioid Cell tumor (PEComa). FYARRO® is a product of Aadi Bioscience, Inc.